Pain, Postoperative
Conditions
Keywords
systemic lidocain
Brief summary
The investigators plan to evaluate the analgesic effect of systemic Lidocaine in addition to general anesthesia during bariatric surgery. Patients will be subdivided into a Lidocaine group and a Control group. The primary outcome will be the proportion of patients suffering from higher pain intensity within the first four hours after bariatric surgery. Secondary outcomes include the average maximal pain intensity during first four hours and during 48 hours, total opiate consumption, occurence of postoperative nausea and vomiting, time to first defecation and total time spent in hospital.
Detailed description
Postoperative pain is a common problem in today's surgery, although pain management techniques have improved in the last years. Systemic application of lidocaine has gained interest since several studies have shown its analgesic, anti-inflammatory and antihyperalgesic properties. In this clinical trial the analgesic effect of intravenously administrated lidocaine is compared with placebo. Despite longstanding use as an antiarrhythmic agent and its use in many clinical trial as analgesic, lidocaine is not licensed for this indication and application. Current studies, setting the focus on abdominal surgery, indicated that the systemic application of lidocaine was associated with fewer intensity of pain at rest and during mobilization and resulted in a decrease of patients'opiate consumption. The intervention to be studied will either be the additional application of systemic lidocaine 1% to general anesthesia in bariatric surgery or the application of placebo. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. The population to be studied will include 140 patients listed for bariatric surgery at the Kantonsspital St. Gallen. Patients, medical practitioner, nurses and investigators will be blinded. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
Interventions
DRUGLidocaine Hydrochloride
The intervention to be studied will be the additional application of systemic lidocaine 1% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Patients, medical practitioner, nurses and investigators will be blinded by utilization of equal appearance and packing of IMPs, which will be fabricated individually for each patient and on request one to two days before surgery by the pharmacy. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
DRUGSaline Solution
The intervention to be studied will be the additional application of NaCl 0.9% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery as a placebo. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
Sponsors
Miodrag Filipovic, Prof. Dr. med.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Measures taken to minimize or avoid bias include randomization and blinding of participants after they have given their informed consent. Blinding of medical practitioner and medical personnel will be conducted by provision of equal looking and packing of IMPs, which will be fabricated individually for each patient and on request one to two days before surgery by the pharmacy.
Intervention model description
The investigators plan to evaluate the analgesic effect of systemic Lidocaine in Addition to general anesthesia during bariatric surgery. * Lidocaine group: perioperative application of systemic Lidocaine up to four hours from end of surgical procedures. * Control group: perioperative application of Placebo (NaCl 0.9%) up to four hours from end of surgical procedures.
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* elective laparoscopic bariatric surgery * ASA classification I - III * age 18 - 80 * given informed consent
Exclusion criteria
* no written consent * allergy to the investigational product * cardiac arrhythmia (pacemaker) * liver dysfunction (Child-Pugh classification A, B or C) * pregnancy * central nervous disease * chronic pain and pre-existing opiate prescription * expected non-compliance * drug/alcohol abuse
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative VAS/NRS Score | 0 - 4 hours after surgery | Any development of VAS/NRS score \> 3 (Visual Analog Scale/Numeric Rating Scale ranging from minimum 0 to maximum 10 points, with 0 points as no pain to 10 points as severe pain) , in hourly measurements within the first four hours after completion of bariatric surgery to evaluate the pain experienced by patients after the surgical intervention |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Average experienced maximal pain during the first four hours and 48 hours after Surgery | 0 - 48 hours after surgery | Average experienced maximal pain during the first four hours and 48 hours (in hourly measurements on post anesthesia care unit (PACU) and in eight-hourly measurements on surgical ward) is assessed by VAS/NRS score (Visual Analog Scale/Numeric Rating Scale ranging from minimum 0 to maximum 10 points, with 0 points as no pain to 10 points as severe pain). |
| Occurence of Postoperative Nausea and Vomiting after Surgery | 0 - 48 hours after surgery | Any event of postoperative nausea and vomiting (PONV) (subdivided by event of no nausea (PONV = 0), event of nausea without vomiting (PONV = 1) and event of nausea with vomiting (PONV = 2)) during first 48 hours after completion of surgery |
| Time to first Defecation | 0 - 48 hours after surgery | Time to first defecation (quantified in hours) |
| Duration of Hospitalization | 0 - 48 hours after surgery | Duration of hospitalization (quantified in days) |
| Total Amount of Opiate Consumption | 0 - 48 hours after surgery | The total amount of opiates (given during surgery and on PACU and administrated by nurse controlled analgesia on surgical ward) |
Countries
Switzerland
Outcome results
None listed